Impact of co-morbidities in COVID -19 infected patients
DOI:
https://doi.org/10.47203/IJCH.2022.v34i01.006%20Keywords:
COVID-19, SARS, MERS, COPD, RT –PCRAbstract
Background- During the COVID- 19 pandemic in the first wave, infected patients age was range from 4 weeks to 90 years and those who have more age and with comorbidities are more susceptible to develop serious illness and have high mortality rates. Objective-To study the association between survivor vs non survivor on the basis of demographic profile and high risk factors. Material & methods: This study was done in the Government Medical College, Kannauj on the COVID-19 patients who were admitted in the isolation wards, from 1st September 2020 to December 31st 2020. Statistical Analysis- Analysis was done using SPSS- 23 trial version software. Results: case fatality rate was 2.7% in this study. Most common symptoms was cough (61.0%) and among these admitted patients the most common comorbidities was hypertension (26.7%), followed by diabetes (20.7%), and COPD (14.0%) respectively. Platelets (< 0.02), post prandial blood sugar (PPBS) (< 0.01) have significant role in survivability of COVID- 19 patients. Conclusion: This study concludes that those patients who were older in age and with comorbidity especially (hypertension, COPD, high PPBS, High platelets) have poorer prognosis as compare to those without.
Downloads
References
Chen N et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395:507–513.
https://doi.org/10.1016/s0140-6736(20)30211-7
Wei-jie Guan et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. : May 2020; 1455(5): 2000547.
Adekunle Sanyaolu, et al .Comorbidity and its Impact on Patients with COVID-19. SN Compr Clin Med: jun 25, 2020: 1–8.
Ravi Dosi, Gaurav Jain and Abhishek Mehta. Clinical Characteristics, Comorbidities, and Outcome among 365 Patients of Coronavirus Disease 2019 at a Tertiary Care Centre in Central India.JAIP : September 2020;68.
Osibogun A et al. Outcomes of COVID-19 patients with comorbidities in southwest Nigeria. PLoS ONE 16(3): e0248281. https://doi.org/10.1371/journal.pone.0248281
Safiya Richardson et al . Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. April 22, 2020; 323(20):2052-2059.
https://doi.org/10.3410/f.737797860.793574198
Divya Goel and Sudhir Kumar. Co-morbid conditions in COVID-19 patients in Uttarakhand state of India. http://www.jogh.org/documents/2021/jogh-11-03029.htm
Downloads
Published
How to Cite
License
Copyright (c) 2022 Indian Journal of Community Health
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.